Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 Mar 4.
Published in final edited form as: Angew Chem Int Ed Engl. 2019 Jan 18;58(10):3119–3122. doi: 10.1002/anie.201812701

Cu-Mediated Aminoquinoline-Directed Radiofluorination of Aromatic C–H Bonds with K18F

So Jeong Lee [a], Katarina J Makaravage [b], Allen F Brooks [a], Peter J H Scott [a],*, Melanie S Sanford [b],*
PMCID: PMC6476334  NIHMSID: NIHMS1522114  PMID: 30605563

Abstract

This communication describes a Cu-mediated ortho-C–H radiofluorination of aromatic carboxylic acids that are protected as 8-aminoquinoline benzamides. The method uses K18F and is compatible with a wide range of functional groups. The reaction is showcased in the high specific activity automated synthesis of the RARβ2 agonist [18F]AC261066.

Keywords: C-H functionalization, PET radiochemistry, Fluorine-18, Late-stage Fluorination, C-H Fluorination

Graphical Abstract

graphic file with name nihms-1522114-f0001.jpg

This communication reports a method for the Cu-mediated ortho-C(sp2)-H radiofluorination of aromatic carboxylic acids that are protected as 8-aminoquinoline benzamides with K18F. Fluorination of 18 examples in up to 62% RCC and high specific activity is reported, including the automated synthesis of [18F]AC261066 (after removal of 8-aminoquinoline auxiliary).


Aryl fluorides are widely prevalent in pharmaceuticals,1,2 and their 18F isotopologs are important for positron emission tomography (PET) imaging.3,4 As such, there is significant interest in methods for the late-stage 18F-fluorination of aromatic scaffolds.5,6 The majority of existing methods for arene radiofluorination require a prefunctionalized starting material. For instance, hypervalent iodine reagents,6c organoborons,6d-f,j,k organostannanes,6g Ni/Pd complexes,6a,b and phenols6h,i have recently been introduced as precursors for nucleophilic radiofluorination reactions. However, this requirement for pre-installed functionality at the target site can be a roadblock for the application of these methods to complex radiotracer targets.

A complementary approach would involve the direct radiofluorination of a C–H bond of an arene substrate. Several strategies have been developed for the radiofluorination of aliphatic7 and benzylic8 C–H bonds. However, analogous transformations of C(sp2)–H substrates have proven considerably more challenging. While C(sp2)–H radiofluorination can be accomplished via electrophilic aromatic substitution (SEAr) with [18F]F2 or [18F]Selectfluor,9 the generation and handling of these reagents requires specialized equipment that is not widely accessible. Additionally, the site- and chemoselectivities of SEAr reactions are typically modest, and the final products generally have low specific activity.10 In principle, these limitations could be addressed through the development of nucleophilic (18F) C(sp2)–H radiofluorination methods. However, in practice, realization of this approach has remained elusive due to the inertness of C(sp2)–H bonds and the electronic mismatch between nucleophilic 18F and most arene substrates.11

An attractive strategy to address these challenges would be to leverage modern advances in transition-metal catalyzed C(sp2)–H functionalization. For example, recent work by Daugulis demonstrated that 8-aminoquinoline directing groups enable Cu-catalyzed ortho-C(sp2)–H activation/nucleophilic fluorination reactions with AgF.12 The directing group is easily cleaved, thus providing access to ortho-fluorinated carboxylic acids. This communication describes translation of this method to a radiofluorination process. While AgF was required in Daugulis’ original transformation, our studies reveal that K18F is optimal for radiofluorination. This nucleophilic radiofluorination of aromatic C–H bonds is applied to a variety of carboxylic acid derivatives and automated to access high specific activity radiotracers.

graphic file with name nihms-1522114-f0004.jpg

We initially examined the Cu-catalyzed radiofluorination of aminoquinoline substrate 1H with Ag18F13 under conditions closely analogous to those reported by Daugulis12 (1H (20 μmol), CuI (5 μmol), N-methylmorpholine N-oxide (NMO, 90 μmol), K2.2.2 (1.33 μmol), Ag18F (2500–3500 μCi) in DMF). However, these conditions did not afford detectable quantities of 118F as determined by radio-TLC and radio-HPLC analysis (Table 1, entry 1). Notably, the Ag19F likely serves two roles in the original Daugulis reaction. First, it acts as the nucleophile to install the C(sp2)–F bond. Second, it serves as a base to sequester the proton that is generated during C–H activation. Since Ag19F is present in 3–4-fold excess relative to 1H, there is sufficient fluoride available for both of these functions. In contrast, under the radiofluorination conditions, the Ag18F is the limiting reagent. We hypothesized that an exogeneous base might be needed to sequester protons while preserving a reservoir of nucleophilic fluoride for the desired C(sp2)–F coupling reaction. Consistent with this hypothesis, the addition of 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) (20 μmol, 1 equiv relative to 1H) led to the formation of the desired product 118F in 26 ± 1% RCC as determined by radio-TLC and confirmed by radio-HPLC (Table 1, entry 2).14 Further optimization revealed that switching from CuI to more soluble (MeCN)4CuOTf resulted in a slightly improved RCC (29 ± 0%; Table 1, entry 3). Under these conditions, the [18F]fluoride source could be changed to readily accessible K18F3 to afford 33 ± 0% RCC of 118F (Table 1, entry 4).

Table 1.

Optimization of C-H Radiofluorinationa

Entry [Cu] M18F NMO DBU RCC (%)b
1 CuI Ag18F -- nd
2 CuI Ag18F 26 ± 1
3 (MeCN)4CuOTf Ag18F 29 ± 0
4 (MeCN)4CuOTf K18F 33 ± 0
5 (MeCN)4CuOTf K18F -- 31 ± 13
6c (MeCN)4CuOTf K18F -- 50 ± 2
[a]

Conditions: 1H (20 μmol), Cu source (5 μmol), additives [NMO (90 μmol), K2.2.2 (1.33 μmol), DBU (20 μmol)], M18F (2500-3500 μCi), DMF (1000 μL).

[b]

RCC was determined by radio-TLC (n ≥ 3); nd = not detected. The identity of 118F was confirmed by radio-HPLC.

[c]

NMM added (90 μmol).

We next examined whether NMO is necessary for this transformation. In the Ag19F reaction (which is conducted under inert atmosphere), NMO acts as the terminal oxidant for Cu. However, the radiochemical reactions are conducted under ambient air, which could directly oxidize the Cu. Indeed, excluding NMO from the Ag18F reaction under otherwise identical conditions resulted in a comparable RCC (31 ± 13%, entry 5),15 although it did negatively impact the run-to-run reproducibility. We evaluated a number of additives to address this latter issue and found that the use of 90 μmol of N-methylmorpholine (NMM), the base counterpart of NMO, resulted in enhanced reproducibility as well as an improved RCC of 50 ± 2% (Table 1, entry 6).

The scope of this reaction was examined using aminoquinolines derived from a variety of substituted benzoic acids.16 As shown in Figure 1, electron-neutral (118F-418F), -withdrawing (518F-1018F),17 and -donating (1118F) substituents were tolerated on the arene ring. Many functional groups, including benzylic C–H bonds, trifluoromethyl, cyano, nitro, ester, amide, and sulfonamide substituents, were compatible. This C(sp2)–H radiofluorination was also effective on pyridine- and indole-derived substrates, providing 1218F and 1318F in moderate RCC. A substrate containing a fluorine substituent at the activated 4-position on the quinoline reacted to afford the ortho-18F-labelled product 1418F in 50% RCC.18 This method was applied to the late-stage radiofluorination of a series of biologically relevant molecules. Four carboxylic acid-containing drugs, probenecid, ataluren, tamibarotene, and AC261066, were converted to the corresponding 8-aminoquinoline benzamides and then subjected to the optimal conditions. The [18F]fluorinated analogues (1518F-1818F, respectively) were obtained in 13–37% RCC.19

Figure 1.

Figure 1.

Substrate Scope. Reported values indicate radiochemical conversion (RCC) determined by radio-TLC for n ≥ 4 runs. The identity of all products was confirmed by radio-HPLC. General conditions: Substrate (20 μmol), (MeCN)4Cu(OTf) (5 μmol), NMM (90 μmol), K2.2.2 (1.33 μmol), DBU (20 μmol), K18F (2500-3500 μCi), DMF (1000 μL), 90-110 °C, 30 min. [a] in cases where other products were observed by radio-HPLC analysis, RCCs from radio-TLC analysis were corrected as described in the Supporting Information.17

A final set of experiments involved automation of this reaction on a TRACERLab FXFN synthesis module and hydrolysis of the aminoquinoline protecting group (Scheme 1). Initial automated studies were conducted with 1H, and afforded 118F in 28 ± 6% (n = 6) automated RCC or, by incorporating semi-preparative HPLC purification, 9 ± 4% (n = 6) isolated decay-corrected radiochemical yield (RCY) and >98% radiochemical purity (RCP). Starting with 1.7 Ci of [18F]fluoride 118F was obtained in 42 ± 3 mCi (n = 3) with high specific activity (6 ± 1 Ci/μmol). Hydrolysis of the aminoquinoline protecting group was then achieved with 4 M NaOH to afford 1918F in 90 ± 2% RCC from 118F (n = 3) and 21 ± 2% RCC based upon starting [18F]fluoride.

Scheme 1.

Scheme 1.

Automated C(sp2)-H Radiofluorination

An analogous method was applied to the synthesis of [18F]AC261066 (2018F), a RARβ2 agonist (Scheme 1).20 Subjecting 18H to the C–H radiofluorination conditions afforded 1818F in 12 ± 2% automated RCC (n = 3). Starting with 1.7 Ci of [18F]fluoride, 1818F was obtained in 36 ± 8 mCi (n = 3) after sep-pak purification, corresponding to 3 ± 1% isolated decay-corrected RCY. Manual hydrolysis of the amide with 4 M NaOH formed [18F]AC261066 (2018F) in 98 ± 1% RCC from 1818F (n = 5, determined by radio-TLC). Overall, the isolated decay-corrected RCY of 2018F was 9 ± 7 mCi (2 ± 1% based upon starting [18F]fluoride, n = 3). The product was obtained in high chemical and radiochemical (>98%) purity and high specific activity (0.80 ± 0.25 Ci/μmol).21

In summary, we describe the Cu-catalyzed, aminoquinoline-directed C(sp2)–H radiofluorination of arene C(sp2)–H bonds with K18F.22 The method has been applied to a variety of substrates, including the active pharmaceutical ingredients of probenecid, ataluren, and tamibarotene. In addition, it has been translated to an automated synthesis of high specific activity doses of RARβ2 agonist [18F]AC261066. We note that the automated radiochemical yields and directing group cleavage procedures will require additional optimization before they can be applied in routine radiosyntheses. In addition, future work should target the use of more practical directing groups as well as non-directed approaches to C–H radiofluorination. However, overall this operationally simple procedure demonstrates proof-of-concept that metal-catalyzed nucleophilic C(sp2)–H radiofluorination is feasible, and that this approach shows promise for the late-stage radiofluorination of bioactive molecules.

Supplementary Material

Supporting Information

Acknowledgements

This work was supported by NIH (R01EB021155) and DOE (DE-SC0012484).

Footnotes

Experimental Section

Detailed experimental details are provided in the supporting information.

References

  • [1] a).Wang J, Sánchez-Roselló M, Aceña JL, del Pozo C, Sorochinsky AE, Fustero S, Soloshonok VA, Liu H, Chem. Rev 2014, 114, 2432. [DOI] [PubMed] [Google Scholar]; b) Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA, J. Med. Chem 2015, 58, 8315. [DOI] [PubMed] [Google Scholar]
  • [2].Meanwell NA, J. Med. Chem, 2018, 61, 5822. [DOI] [PubMed] [Google Scholar]
  • [3].Ametamey SM, Honer M, Schubiger PA, Chem. Rev, 2008, 108, 1501. [DOI] [PubMed] [Google Scholar]
  • [4] a).Alauddin MM, Am. J. Nucl. Med. Mol. Imaging, 2012, 2, 55. [PMC free article] [PubMed] [Google Scholar]; b) Brust P, van den Hoff J, Steinbach J, Neurosci. Bull 2014, 30, 777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].For recent reviews and perspectives on late-stage fluorination, see:Brooks AF, Topczewski JJ, Ichiishi N, Sanford MS, Scott PJH, Chem. Sci 2014, 5, 4545.Campbell MG, Ritter T, Chem. Rev 2015, 115, 612.Preshlock S, Tredwell M, Gouverneur V, Chem. Rev 2016, 116, 719.Sanford MS, Scott PJH, ACS Cent. Sci 2016, 2, 128.Campbell MG, Mercier J, Genicot C, Gouverneur V, Hooker JM, Ritter T, Nat. Chem 2017, 9, 1.
  • [6] a).Lee E, Kamlet AS, Powers DC, Neumann CN, Boursalian GB, Furuya T, Choi DC, Hooker JM, Ritter T, Science 2011, 334, 639. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Lee E, Hooker JM, Ritter T, J. Am. Chem. Soc 2012, 134, 17456. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Ichiishi N, Brooks AF, Topczewski JJ, Rodnick ME, Sanford MS, Scott PJH, Org. Lett 2014, 16, 3224. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Tredwell M, Preshlock SM, Taylor NJ, Gruber S, Huiban M, Passchier J, Mercier J, Génicot C, Gouverneur V, Angew. Chem., Int. Ed 2014, 53, 7751. [DOI] [PubMed] [Google Scholar]; e) Mossine AV, Brooks AF, Makaravage KJ, Miller JM, Ichiishi N, Sanford MS, Scott PJH, Org. Lett 2015, 17, 5780. [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Zlatopolskiy BD, Zischler J, Krapf P, Zarrad F, Urusova EA, Kordys E, Endepols H, Neumaier B, Chem. Eur. J 2015, 21, 5972. [DOI] [PubMed] [Google Scholar]; g) Makaravage KJ, Brooks AF, Mossine AV, Sanford MS, Scott PJH, Org. Lett. 2016, 18, 5440. [DOI] [PMC free article] [PubMed] [Google Scholar]; h) Neumann CN, Hooker JM, Ritter T, Nature, 2016, 534, 369. [DOI] [PMC free article] [PubMed] [Google Scholar]; i) Beyzavi MH, Mandal D, Strebl MG, Neumann CN, D’Amato EM, Chen J, Hooker JM, Ritter T ACS Cent. Sci, 2017, 3, 944. [DOI] [PMC free article] [PubMed] [Google Scholar]; j) Mossine AV, Brooks AF, Bernard-Gauthier V, Bailey JJ, Ichiishi N, Schirrmacher R, Sanford MS, Scott PJH, J. Labelled Compd. Radiopharm, 2018, 61, 228. [DOI] [PMC free article] [PubMed] [Google Scholar]; k) Taylor NJ, Emer E, Preshlock S, Schedler M, Tredwell M, Verhoog S, Mercier J, Genicot C, Gouverneur V, J. Am. Chem. Soc, 2018, 139, 8267. [DOI] [PubMed] [Google Scholar]
  • [7] a).Nodwell MB, Yang H, Čolović M, Yuanm Z, Merkens H, Martin RE, Bénard F, Schaffer P, Britton R, J. Am. Chem. Soc, 2017, 139, 3595. [DOI] [PubMed] [Google Scholar]; b) Britton R, Yuan Z, Nodwell M, Yang H, Malik N, Merkens H, Bernard F, Martin R, Schaffer P. Angew. Chem. Int. Ed, 2018, 57, 12733. [DOI] [PubMed] [Google Scholar]
  • [8] a).Huang X, Liu W, Ren H, Neelamegam R, Hooker JM, Groves JT, J. Am. Chem. Soc, 2014, 136, 6842. [DOI] [PubMed] [Google Scholar]; b) Huang X, Liu W, Hooker JM, Groves JT, Angew. Chem. Int. Ed, 2015, 54, 5241. [DOI] [PubMed] [Google Scholar]; c) Liu W, Huang X, Placzek MS, Krska SW, McQuade P, Hooker JM, Groves JT, Chem. Sci, 2018, 9, 1168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Jacobson O, Kiesewetter DO, Chen X, Bioconjugate Chem, 2015, 26, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Bergman J, Solin O, Nucl. Med. Biol, 1997, 24, 677. [DOI] [PubMed] [Google Scholar]
  • [11].McCammant MS, Thompson S, Brooks AF, Krska SW, Scott PJH, Sanford MS, Org. Lett, 2017, 19, 3939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Truong T, Klimovica K, Daugulis O, J. Am. Chem. Soc. 2013, 135, 9342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Scott PJH, Brooks AF, Ichiishi N, Sanford MS, Preparation of Ag18F and its use in the Synthesis of PET Radiotracers, U.S. Patent 2016/0317682 A1, November 3, 2016.
  • [14].Other bases were also compatible (e.g. comparable RCCs could be obtained using 1,5-diazabicyclo[4.3.0]non-5-ene; see Supporting Information).
  • [15].When Table 1, entry 5 was set up in a glovebox and kept under an inert atmosphere the RCC dropped prohibitively (to 6 ± 4%), further consistent with the role of air as the oxidant.
  • [16].Product identities were confirmed by radio-HPLC. To further confirm that radiofluorination occurred at the expected ortho-site (rather than on the quinoline ring) we conducted control experiments and demonstrated baseline separation of regioisomeric products by HPLC (see Supporting Information).
  • [17].Some arenes bearing electron-withdrawing substituents give rise to minor side products. We ruled out the formation of side products derived from competing SNAr reactions (see Supporting Information), but have not been able to positively identity the side products to date.
  • [18] a).Ding J, Zhang Y, Li J, Org. Chem. Front. 2017, 4, 1528. [Google Scholar]; b) Chen H, Li P, Wang M, Wang L, Eur. J. Org. Chem. 2018, 2018, 2091. [Google Scholar]
  • [19].Products 15–18 contain functional groups that could potentially direct C-H fluorination elsewhere in the molecule (e.g. 17H contains 2 amide groups). Small impurity peaks were detected in the crude radio-HPLC traces of these products; however, 1518F-1818F were the major products in each case, and they appear to be readily separable from the side products formed in the reaction.
  • [20].Lund BW, Piu F, Gauthier NK, Eeg A, Currier E, Sherbukhin V, Brann MR, Hacksell U, Olsson R, J. Med. Chem, 2005, 48, 7517. [DOI] [PubMed] [Google Scholar]
  • [21].These unoptimized automation results demonstrate that this method can be used to prepare sufficient amounts of radiotracers for pre-clinical evaluation in rodents and non-human primates. We expect that yields can be further improved through careful optimization of the automated method. This work is currently underway, along with qualification of a synthesis and formulation of 2018F for preclinical use.
  • [22].Radioiodination of this scaffold has been reported. See: Deady LW, Desneves J, Tilley LMA, J. Labelled Compd. Radiopharm, 2000, 43, 977. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

RESOURCES